title: Celecoxib-induced nonoliguric acute renal failure.
abstract: OBJECTIVE
  To report a case of nonoliguric acute renal failure secondary to use of celecoxib in a patient with rheumatoid arthritis.
  
  
  METHODS
  A 43-year-old Hispanic woman started receiving celecoxib 200 mg/d for treatment of rheumatoid arthritis. Fourteen days after initiating therapy, she developed nonoliguric acute renal failure. Celecoxib was discontinued. Renal function improved, but had not returned to normal 30 days after presentation.
  
  
  CONCLUSIONS
  Only 2 cases of reversible oliguric acute renal failure and volume overload have been reported 13 and 14 days after initiating therapy with celecoxib. Renal function in the 2 patients returned to baseline after treatment with diuretics. To our knowledge, the development of nonoliguric acute renal failure secondary to treatment with celecoxib has not previously been reported.
  
  
  CONCLUSIONS
  Celecoxib can probably result in reversible, or nonoliguric, acute renal failure. Although renal function improves after discontinuation of celecoxib, it may not return to baseline. Celecoxib should be used cautiously in individuals at risk of developing acute renal failure.
authors.affiliation: Division of Critical Care Medicine, Department of Medicine, St. Barnabas Hospital, Weill Medical College of Cornell University, Bronx, NY, USA. salkuja@aol.com
authors.forename: Samer
authors.initials: S
authors.lastname: Alkhuja
authors.forename: Robert A
authors.initials: RA
authors.lastname: Menkel
authors.forename: Mamata
authors.initials: M
authors.lastname: Alwarshetty
authors.forename: Ahmad M
authors.initials: AM
authors.lastname: Ibrahimbacha
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000473:pathology; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib